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Inhibition of Connective Tissue Growth Factor
Overexpression in Diabetic Retinopathy by SERPINA3K
via Blocking the WNT/-Catenin Pathway
Bin Zhang, Kevin K. Zhou, and Jian-xing Ma
OBJECTIVE—Connective tissue growth factor (CTGF) is a
major ﬁbrogenic factor. Increased retinal CTGF levels have been
implicated to play a role in diabetic retinopathy. SERPINA3K is a
serine proteinase inhibitor, and its levels were decreased in
retinas with diabetic retinopathy. The purpose of this study was
to investigate the role of SERPINA3K in the regulation of CTGF
and ﬁbrogenesis and its mechanism of action.
RESEARCH DESIGN AND METHODS—Adenovirus express-
ing SERPINA3K was injected intravitreally into streptozotocin-
induced diabetic rats. CTGF expression was measured using
Western blot analysis and real-time RT-PCR. Fibrosis was eval-
uated by quantifying retinal ﬁbronectin using enzyme-linked
immunosorbent assay. Wnt pathway activation was determined
by phosphorylation of LDL receptor–related protein 6, a corecep-
tor of Wnt ligands, and stabilization of -catenin, an essential
effector of the canonical Wnt pathway.
RESULTS—Ad-SERPINA3K attenuated the CTGF and ﬁbronec-
tin overexpression in retinas of diabetic rats. In cultured retinal
cells, SERPINA3K blocked the overproduction of CTGF induced
by high glucose. Dickkopf-1, a speciﬁc Wnt antagonist, also
attenuated the high-glucose–induced CTGF overexpression, in-
dicating a role of Wnt signaling in CTGF overexpression in
diabetes. Similarly, increased SERPINA3K blocked Wnt pathway
activation in diabetic retinas and in cells treated with high
glucose. Further, SERPINA3K also attenuated the Wnt3a-induced
activation of the canonical Wnt pathway and the overexpression
of CTGF.
CONCLUSION—SERPINA3K is an antiﬁbrogenic factor, and its
antiﬁbrogenic activity is through blocking the Wnt pathway.
Decreased SERPINA3K levels may contribute to the ﬁbrosis in
diabetic retinopathy. Diabetes 59:1809–1816, 2010
S
ERPINA3K, a serine proteinase inhibitor (serpin),
is expressed in the liver, kidney, pancreas, and
retina (1–3). SERPINA3K speciﬁcally binds to
tissue kallikrein to form a covalent complex and
inhibits proteolytic activities of tissue kallikrein (3) and is
believed to participate in the regulation of vasodilation
and local blood ﬂow via interactions with the kallikrein-
kinin system (4). Later studies suggest that SERPINA3K
has other functions independent of inhibition of tissue
kallikrein. For example, SERPINA3K has been found to
inhibit retinal neovascularization in ischemia-induced ret-
inopathy, which is not dependent on its interactions with
the kallikrein-kinin system (5). Further, in a diabetic rat
model, SERPINA3K levels have been shown to decrease in
retinas, suggesting that decreased SERPINA3K levels may
contribute to diabetic retinopathy (6).
Diabetic retinopathy is one of the leading causes of
blindness (7). In advanced stages of diabetic retinopathy,
retinal ﬁbrosis occurs and ﬁbrovascular contraction can
cause hemorrhages and retinal detachment (7,8). Connec-
tive tissue growth factor (CTGF) is a proﬁbrogenic factor
that stimulates ﬁbroblast proliferation, cell adhesion, and
extracellular matrix production (9,10). The potential role
of CTGF in pathological ﬁbrosis has been established (11),
and CTGF has been suggested to be an attractive thera-
peutic target in some ﬁbrotic diseases (12). The protein
and mRNA levels of CTGF were found to be elevated in
retinas with diabetic retinopathy (13), and the roles of
CTGF in ﬁbrovascular proliferation and thickening of
capillary basement membrane were also demonstrated in
proliferative diabetic retinopathy (13–16). All of these
previous ﬁndings suggest a therapeutic potential for anti-
CTGF therapy in diabetic retinopathy.
Wnts are a group of secreted, cysteine-rich glycopro-
teins (17). As shown in online appendix Figure S1 (avail-
able at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-1056/DC1), in the absence of Wnt ligands,
transcription factor -catenin, a downstream effector of
the canonical Wnt pathway, is phosphorylated by a protein
complex containing glycogen synthase kinase (GSK)-3 in
the cytosol and constantly degraded to prevent its accu-
mulation (18,19). Upon binding of certain Wnt ligands, the
Frizzled (Fz) receptor dimerizes with the coreceptor, LDL
receptor–related protein (LRP) 5 or 6, forming a receptor/
coreceptor complex (17). As a result, the downstream
signaling is stimulated, including phosphorylation of
LRP5/6 and stabilization of -catenin (20,21). -Catenin is
subsequently translocated into the nucleus, associates
with T-cell factor (TCF) for DNA binding, and regulates
expression of target genes including CTGF (17).
The Wnt signaling pathway is involved in multiple
physiological and pathological processes. It has been well
studied in embryogenesis and carcinogenesis (22). Recent
evidence suggests that the Wnt pathway is also important
in ocular diseases; for example, mutations in the Fz
receptor and LRP coreceptor have been shown to associ-
ate with the vascular developmental defects (23). Further-
more, it has been revealed that Wnt signaling is re-
sponsible for pathological ﬁbrosis in the lung, suggesting
that inhibition of Wnt signaling, such as Wnt antagonists,
may represent a therapeutic option (24–27). As a proﬁbro-
genic factor, CTGF was also found to be regulated by Wnt
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there is little previous evidence to implicate Wnt signaling
in ﬁbrosis in the retina with diabetic retinopathy.
In the present study, we have investigated the inhibitory
effect of SERPINA3K on the hyperglycemia-induced CTGF
overexpression and Wnt pathway activation and further
determined if the beneﬁcial effects of SERPINA3K in diabetic
retinopathy are through the Wnt antagonistic activity.
RESEARCH DESIGN AND METHODS
Cell culture. A cell line derived from rat retinal Mu ¨ller cells (rMCs) (rMC-1;
a kind gift from Dr. Vijay Sarthy at Northwestern University), were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Cellgro, Manassas, VA) contain-
ing 10% FBS (Invitrogen, Carlsbad, CA) (30). Human telomerase reverse
transcriptase (HTERT)-immortalized retinal pigment epithelial (RPE) cell line
(HTERT-RPE), a cell line derived from human RPE cells, was purchased from
the American Type Culture Collection (ATCC) (Manassas, VA) and cultured in
DMEM containing 10% FBS following ATCC recommendations. L-cells and
L-cells stably expressing Wnt3A (L-Wnt3a) were purchased from the ATCC and
cultured in DMEM containing 10% FBS and 0.4 mg/ml G-418 (Invitrogen). The
cells and conditioned media (1 g/l glucose, 1% FBS) were harvested following
the procedure recommended by the ATCC. The cultured cells were starved in
1 g/l glucose (5 mmol/l) DMEM containing 1% FBS overnight before treatment.
For the high-glucose treatment, the cells were exposed to 30 mmol/l D-glucose
(Sigma, St. Louis, MO), and the low-glucose control included 5 mmol/l
D-glucose and 25 mmol/l L-glucose (Sigma) in the culture medium.
Experimental animals. Brown Norway (BN) rats were purchased from
Charles River Laboratories (Wilmington, MA). Care, use, and treatment of all
animals in this study were in strict agreement with the Association for
Research in Vision and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research and the guidelines in the care and use of
laboratory animals set forth by the University of Oklahoma.
Induction of experimental diabetes. Experimental diabetes was induced
as described previously (31). Brieﬂy, BN rats (8 week of age) were given a
single intraperitoneal injection of streptozotocin (STZ; 50 mg/kg in 10 mmol/l
citrate buffer, pH 4.5) after an overnight fast. Serum glucose levels were
monitored 48 h after the STZ injection and every 2 weeks thereafter, and only
the animals with blood glucose levels 350 mg/dl were used as STZ-induced
diabetic rats.
Recombinant proteins, adenovirus, plasmids, transfection, and re-
porter Assay. The SERPINA3K cDNA was cloned into the pET28 vector
(Novagen, Madison, WI), and the construct was transformed into E. coli strain
BL-21/DE3 (Novagen). The expression and puriﬁcation followed the protocol
described previously (5). Endotoxin levels were measured using a limulus
amebocyte kit (Biowhittaker, Walkersville, MD). BSA (Sigma) was used as
protein control for SERPINA3K. Recombinant Dickkopf (DKK)-1 protein was
purchased from R&D Systems (Minneapolis, MN). To clone the SERPINA3K
cDNA, total RNA was extracted from the liver and was reverse transcribed to
cDNA. The full-length sequence of SERPINA3K containing the signal peptide
was cloned into the shuttle vector. The adenoviral vector used in the study is
human adenovirus serotype 5 (Ad5). Adenoviruses expressing SERPINA3K
and LacZ were generated using AdEasy systems from Qbiogene (Irvine, CA)
following manufacturer’s protocol. These adenoviruses were puriﬁed using
Adeno-X Virus Puriﬁcation Kits from BD Biosciences (San Jose, CA). TOP-
FLASH vector was constructed as described (32). Fugene 6 (Roche Applied
Science, Indianapolis, IN) was used for transfection following manufacturer’s
protocol. Luciferase reporter assays were performed in 12-well plates. The
TOPFLASH construct and renilla luciferase pRL-TK vector were cotransfected
into the cells. TOPFLASH activity was measured using the dual-luciferase
reporter system (Promega, Madison, WI) and normalized by renilla luciferase
activity.
Real-time RT-PCR. Total RNA was isolated using an RNeasy Mini Kit
(Qiagen Sciences, Germantown, MD). mRNA was reverse transcribed to cDNA
using a TaqMan kit from Roche. This cDNA was then used for speciﬁc
real-time PCR. The speciﬁc primers for CTGF (5-AAGACCTGTGGGAT
GGGC-3 and 5-TGGTGCAGCCAGAAAGCTC-3) were synthesized from Inte-
grated DNA Technologies (San Diego, CA). To normalize the variation of the
amount of mRNA in each reaction, 18S rRNA (primers: 5-TTTGTTGGTTT
TCGGAACTGA-3 and 5-CGTTTATGGTCGGAACTACGA-3) was simulta-
neously processed in the same sample as an internal control. iQ SYBR Green
Supermix from BioRad (Hercules, CA) was used for real-time PCR following
the manufacturer’s procedure.
Standard curves for CTGF primers and 18S primers were constructed using
serial 1–10 dilutions of the cDNA product from RT reaction (online appendix
Fig. S6). The efﬁciency of CTGF primers was 99.46% and the efﬁciency of 18S
primers was 97.43%. Dilutions of 1:1,000, 1:100, and 1:10 were used in the
assay, and all of the samples were diluted by 1:100 for the real-time PCR. To
calculate relative changes in gene expression, we used the - method
following the BioRad’s introduction.
Western blot analysis. The same amounts of proteins from the cytosolic
fraction, total cell lysates, and retinal homogenates were resolved by SDS-
PAGE (8 or 10%) and analyzed by Western blotting using speciﬁc antibodies.
For cytosolic -catenin measurement, cells were lysed by three freeze/thaw
cycles in PBS with a protease inhibitor cocktail (Roche Applied Science)
followed by centrifugation, and the supernatants were isolated for Western
blot analysis. For total cell lysates, harvested cells were sonicated in radio-
immunoprecipitation assay buffer (Cell Signaling Technology, Danvers, MA)
containing 1% SDS. For retinal homogenate preparation, retinas were homog-
enized in PBS with a protease inhibitor cocktail using a soft-tissue pestle
(Fisher Scientiﬁc, Pittsburgh, PA). Antibodies for CTGF, LRP6, and -catenin
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and used at
1:400, 1:500, and 1:2,500 dilutions, respectively. Antibody for -actin (1:3,000)
was purchased from Invitrogen. Antibodies for phosphorylated LRP6 (S1490),
phosphorylated -catenin (S33/37/T41), phosphorylated GSK3 (S9), GSK3,
and histone H3 were purchased from Cell Signaling Technology and used at
1:500 dilution for the ﬁrst two antibodies and 1:2,500 dilution for the last three
antibodies. The monoclonal antibody for SERPINA3K (1:1,000) was generated
using the recombinant SERPINA3K through contracted service with Protein-
tech Group (Chicago, IL).
Because of the posttranslational modiﬁcations, CTGF can display multiple
bands with different molecular weights, which has been reported in the
literature (33). Typically, a 36- or 38-kD band, or double bands at these
molecular weights, can be detected, dependent on the tissue, cell type, and
treatment. In the present study, CTGF showed double bands (36/38 kD) in the
Western blotting data using the HTERT–RPE-1 cell lysate.
Enzyme-linked immunosorbent assay for ﬁbronectin. Fibronectin con-
centrations in the retina homogenates were measured using an enzyme-linked
immunosorbent assay (ELISA) kit purchased from Assaypro (Winﬁeld, MO),
according to manufacturer’s instruction. The working range of the ﬁbronectin
ELISA kit used here is 4–1,000 ng/ml. All of the samples were measured in the
linear part of the working range. The assay coefﬁcients of variation are 2%.
The total protein concentration was measured by Bradford protein assay.
Statistical analysis. Student t test (two tailed) was used for comparisons
between two groups. ANOVA was used for comparisons between groups in
Table 1. Statistical signiﬁcance was accepted when the P value was 0.05.
RESULTS
Clinical characteristics of diabetic animals. Two
months after the induction of diabetes, the ATZ-induced
diabetic rats received an intravitreal injection of adenovi-
rus expressing SERPINA3K (Ad-SA3K, 5  10
7 pfu/eye),
and the same titer of adenovirus expressing LacZ (Ad-
LacZ) was injected for control. The rats were separated
into four groups: normal rats without STZ-induced diabe-
tes (control group); rats with STZ-induced diabetes (DM
group); STZ-induced diabetic rats with injection of Ad-
SA3K (DM-SA3K group), and STZ-induced diabetic rats
with injection of Ad-LacZ (DM-LacZ group). There were
8–10 rats in each group. Before the STZ injection, all of
these rats had similar blood glucose levels (100 mg/dl) and
similar body weights (150 g). Three months after STZ
injection, average body weight of the DM group (149  16 g)
was signiﬁcantly lower than in nondiabetic control group
(187  16 g) (P  0.05). At each time point, there was no
signiﬁcant blood glucose or body weight difference between
the DM group, the DM-LacZ group, and the DM-SA3K group
(Table 1), suggesting that the ocular adenovirus injection had
no systemic effect in the diabetic animals.
A novel antiﬁbrogenic activity of SERPINA3K in the
retina with diabetic retinopathy. To investigate the
effect of SERPINA3K on ﬁbrosis in the retina with diabetic
retinopathy, we measured the retinal levels of ﬁbronectin
in the STZ-induced diabetic rats. Fibronectin is an extra-
cellular matrix protein, and overproduction of ﬁbronectin
has been shown to contribute to capillary basement mem-
brane thickening in diabetic retinopathy (34). Consistent
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ﬁbronectin levels were signiﬁcantly higher in the retinas of
the diabetic rats compared with that in nondiabetic con-
trol subjects (Fig. 1). Ad-SA3K blocked retinal ﬁbronectin
overexpression in diabetic rats (Fig. 1), suggesting an
antiﬁbrogenic activity of SERPINA3K.
Retinal endothelial cells and pericytes are two major
vascular cell types that are profoundly affected in diabetic
retinopathy, and their dysfunctions contribute to the blood-
retinal barrier breakdown in diabetic retinopathy (35–37).
Since these cells are also the sources of ﬁbronectin produc-
tion responsible for thickening of the basement membrane,
we measured the concentration of ﬁbronectin in primary
retinal pericytes and endothelial cells by ELISA. The high-
glucose–induced overproduction of ﬁbronectin was attenu-
ated by SERPINA3K in both of the cell types (Fig. S2).
Inhibitory effects of SERPINA3K on CTGF overex-
pression. The inhibitory effect of SERPINA3K on CTGF
was evaluated in the STZ-induced diabetic rats. Four
weeks after the injection of Ad-SA3K or Ad-LacZ, the
retinas were dissected following a thorough perfusion to
remove the blood in the retinal vasculature. As measured
by Western blot analysis, retinal levels of SERPINA3K
were decreased in the untreated diabetic rats, compared
with that in nondiabetic rats (Fig. 2A and B). The Ad-SA3K
injection resulted in an increase of SERPINA3K levels in
the retinas of the diabetic rats (Fig. 2A and B). Retinal
levels of CTGF were signiﬁcantly increased in the retinas
of untreated diabetic rats, compared with nondiabetic rats
at the same age. The injection of Ad-SA3K mitigated the
overexpression of CTGF in the retinas compared with the
control Ad-LacZ virus (Fig. 2A and B).
It has been shown that RPE cells and rMCs are two
major cell types expressing CTGF in the proliferative
vitreoretinopathy (38). The diabetes-induced blood-retinal
barrier breakdown occurs predominantly at the level of
the retinal blood vessels (39). However, the failure of the
RPE barrier also occurs at an lower level, suggesting that
the pathological change of the RPE is involved in diabetes
(39). To evaluate the direct effect of SERPINA3K on
hyperglycemia-mediated CTGF overexpression in vitro,
HTERT–RPE-1 cells (human RPE cell line) and rMC-1 (rat
rMC line) were exposed to media containing 30 mmol/l
D-glucose (high glucose). CTGF expression was signiﬁ-
cantly elevated by high glucose exposure, when compared
with low glucose control (5 mmol/l D-glucose and 25
mmol/l L-glucose, low glucose). SERPINA3K blocked the
high-glucose–induced CTGF overexpression in a dose-
dependent manner in both of the cell lines (Fig. 2C and D).
To further study the mechanism for the regulation of
CTGF by SERPINA3K, real-time RT-PCR was performed to
measure mRNA levels of CTGF in the retinas and cultured
retinal cells. The mRNA levels of CTGF were increased in
retinas with diabetic retinopathy and decreased by Ad-
SA3K (Fig. 3A). Similarly, exposure to high-glucose media
for 16 h signiﬁcantly elevated CTGF mRNA levels in both
HTERT–RPE-1 cells and rMC-1 cells. In a time course
experiment, the cells were exposed to high-glucose me-
dium for 0–24 h. The high-glucose treatment continu-
ously increased the CTGF mRNA level after4ho f
exposure (online appendix Fig. S3). The high-glucose–
induced CTGF mRNA overexpression was attenuated by
100 nmol/l SERPINA3K (Fig. 3B and C). Taken together,
these results indicate that SERPINA3K blocks the hy-
perglycemia-induced CTGF expression at the transcrip-
tion level.
The role of the high-glucose–induced Wnt/-catenin
signaling in CTGF overexpression. To explore the
signaling pathway mediating the inhibitory effect of
SERPINA3K on CTGF transcription, we ﬁrst investigated
cell signaling responsible for CTGF overexpression in-
TABLE 1
Physiological parameters of diabetic rats
No Ad-IVT Diabetes with Ad-IVT
Control Diabetes P value LacZ SA3K P value
Blood glucose (mg/dl)
Time after STZ injection
	1 day 97  89 9  6 0.955 107  11 103  12 0.789
3 days — 544  55 — 515  79 528  59 0.916
1 month 94  8 524  59 0.001 531  66 530  72 1.000
2 months 98  4 521  67 0.001 533  88 517  77 0.965
3 months 108  22 543  37 0.001 534  61 530  50 0.992
Body weight (g)
Time after STZ injection
	1 day 151  13 145  9 0.790 148  15 150  9 0.993
3 days — 143  12 — 146  15 145  9 0.979
1 month 176  15 146  13 0.002 152  17 149  13 0.983
2 months 183  11 147  17 0.001 150  19 151  15 1.000
3 months 187  16 149  16 0.001 149  20 152  17 0.976
Data are means  SD. n 
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FIG. 1. SERPINA3K attenuated overexpression of ﬁbronectin in the
retinas with diabetic retinopathy. Ad-SA3K and Ad-LacZ were injected
separately into the vitreous of diabetic rats, and the retinas were
dissected 4 weeks following the injection. Retinal ﬁbronectin levels
were measured by ELISA and expressed as percentage of the retinal
ﬁbronectin level in the nondiabetic rats (means  SD, n  6). *P <
0.05.
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(TBE) site was identiﬁed in the promoter region of the
CTGF gene, and CTGF has been shown to be a target gene
of -catenin-TCF/LEF transcription factor (33), a down-
stream effector of the canonical Wnt pathway, we investi-
gated the role of the Wnt pathway in the CTGF
overexpression in diabetes. A number of Wnt ligands and
Fz receptors and both LRP5 and -6 were found to express
in the cultured HTERT–RPE-1 cells by RT-PCR, suggesting
that this cell line is a suitable model for Wnt signaling
studies (online appendix Fig. S4). As phosphorylation of
LRP6 is a critical step in the canonical Wnt pathway
activation (40), we measured phosphorylated LRP6 (p-
LRP6) levels. As shown by Western blot analysis using an
antibody speciﬁc for p-LRP6, phosphorylation of the en-
dogenous LRP6 was increased in the RPE cells exposed to
30 mmol/l glucose, compared with that in control cells
exposed to the low-glucose medium (Fig. 4A). In the same
cell line, cytosolic -catenin levels were also elevated by
the high-glucose medium in an exposure time-dependent
manner (Fig. 4A). Further, under high-glucose conditions,
phosphorylated -catenin levels were decreased, com-
pared with that in low-glucose control (online appendix
Fig. S5A), while nuclear -catenin levels were elevated
(online appendix Fig. S5B). Consistently, GSK3 phos-
phorylation (inactive form) was increased (online appen-
dix Fig. S5A). In vivo, cytosolic -catenin levels in the
retina homogenates were also signiﬁcantly elevated in the
diabetic rats, indicating an activation of the canonical Wnt
pathway in retinas with diabetic retinopathy (Fig. 4C and
D). Further, when the Wnt pathway was blocked by
DKK-1, a speciﬁc inhibitor of the canonical Wnt pathway,
the high-glucose–induced CTGF overexpression was at-
tenuated (Fig. 4B), suggesting that the Wnt pathway acti-
vation induced by high glucose and diabetes is responsible
for the CTGF overexpression.
Inhibitory effects of SERPINA3K on Wnt/-catenin
signaling in diabetic retinopathy and high-glucose–
treated retinal cells. To further investigate whether
SERPINA3K inhibits the Wnt pathway in high-glucose–
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FIG. 2. SERPINA3K attenuated overexpression of CTGF in the retinas with diabetic retinopathy and in retinal cells treated with high glucose.
A: STZ-induced diabetic rats (DM) received an intravitreal injection of Ad-SA3K, with Ad-LacZ as control. Four weeks after the injection, retinal
levels of SERPINA3K and CTGF were measured by Western blot analysis using 100 g of retinal proteins from each rat. B: Retinal levels of
SERPINA3K and CTGF were quantiﬁed by densitometry from three independent experiments and normalized by -actin levels (*P < 0.05,
means  SD, n  6). C and D: rMC-1 cells (C) and HTERT RPE-1 cells (D) were exposed to low-glucose (LG, 5 mmol/l D-glucose  25 mmol/l
L-glucose) and high-glucose (HG, 30 mmol/l D-glucose) media with various concentrations of SERPINA3K for 24 h. Cellular CTGF levels were
measured by Western blot analysis and normalized by -actin levels.
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FIG. 3. SERPINA3K decreased CTGF mRNA levels in the diabetic retinas and in high-glucose–treated cells. A: Ad-SA3K and Ad-LacZ were injected
intravitreally into the eyes of diabetic rats, and the retinas were dissected 4 weeks after the injection. B and C: rMC-1 cells (B) and HTERT RPE-1
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0.05.
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delivered into the RPE cell culture medium containing
high glucose and into the vitreous humor of diabetic rats.
After a 6-h exposure, SERPINA3K decreased the high-
glucose–induced phosphorylation of LRP6 and accumula-
tion of -catenin in a concentration-dependent manner
(Fig. 5A). SERPINA3K at 100 nmol/l decreased p-LRP6
and cytosolic -catenin to levels similar to that in the
low-glucose control (Fig. 5A). Similarly, 100 nmol/l
SERPINA3K completely reversed the high-glucose–in-
duced changes of phosphorylated -catenin levels, nuclear
-catenin levels, and phosphorylated GSK3 levels (online
appendix Fig. S5A and B). In STZ-induced diabetic rats,
the injection of Ad-SA3K also blocked the accumulation of
cytosolic -catenin in the retina, compared with the con-
trol virus Ad-LacZ, suggesting an inhibitory effect of
SERPINA3K on the canonical Wnt pathway in diabetes
(Fig. 5B and C).
The Wnt inhibitory effect of SERPINA3K was respon-
sible for CTGF regulation. To determine whether
SERPINA3K also blocks CTGF expression induced by Wnt
signaling, the RPE cells were exposed to a 50% Wnt3a
conditioned medium, with the 50% L-cell medium as
control. The Wnt3a-conditioned medium elevated p-LRP6
and cytosolic -catenin levels in the RPE cells (Fig. 6A and
B). SERPINA3K at 100 nmol/l blocked the increase of
p-LRP6 and -catenin levels induced by Wnt3a (Fig. 6A
and B). TOPFLASH is a luciferase reporter construct
under the control of a promoter containing the TCF/LEF-
binding sites. To measure -catenin–dependent reporter
gene transcription, TOPFLASH activity assay was per-
formed to further conﬁrm the inhibitory effect of
SERPINA3K on Wnt signaling. The RPE cells were trans-
fected with the TOPFLASH construct and then incubated
with the 50% Wnt3a-conditioned medium. TOPFLASH as-
say showed that Wnt3a induced an approximately three-
fold increase in TOPFLASH reporter (TCF/LEF) activity,
which was attenuated by SERPINA3K (Fig. 6C). These
results indicated that SERPINA3K is a Wnt inhibitor.
To determine the effect of SERPINA3K on the Wnt-
induced CTGF expression, the 50% Wnt3a-conditioned
medium was used to treat the cultured RPE cells. Wnt3a,
as well as high glucose, induced CTGF overexpression in
the RPE cells (Fig. 6D). Correlating with its inhibitory
effect on Wnt signaling, SERPINA3K also inhibited the
Wnt3a-induced CTGF upregulation, similar to that in the
high-glucose model (Fig. 6D).
DISCUSSION
SERPINA3K is an extracellular serpin and has been found
to function as an antiangiogenic factor (5) and an anti-
inﬂammatory factor (41). Our previous studies showed
that SERPINA3K levels are decreased in the retina of
diabetic rats (6). The present study revealed a novel
antiﬁbrogenic activity of this serpin, as it inhibits CTGF
overexpression and reduces the production of extracellu-
lar matrix in retina with diabetic retinopathy. These ﬁnd-
ings suggest that decreased SERPINA3K levels in the
diabetic retina may contribute to pathological ﬁbrosis in
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FIG. 4. Wnt/-catenin signaling was responsible for the high-glucose–induced CTGF overexpression. A: HTERT RPE-1 cells were exposed to high
glucose for different durations as indicated. p-LRP6 levels were measured by Western blot analysis using 100 g of total proteins with an antibody
speciﬁc for p-LRPE6, and cytosolic -catenin levels were determined by Western blot analysis using 20 g cytosolic proteins. B: HTERT RPE-1
cells were exposed to low glucose and high glucose media with 100 nmol/l DKK1 or BSA. After 24-h treatment of the cells, CTGF levels were
measured by Western blot analysis. C and D: The retinas were dissected from nondiabetic rats and diabetic rats. -Catenin levels in the retinal
homogenates were measured by Western blot analysis (C) and quantiﬁed by densitometry (D)( * P < 0.05, means  SD, n  6).
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the inhibitory effect of SERPINA3K on CTGF overexpres-
sion is through mitigating the Wnt signaling activation
induced by diabetes.
Fibrosis is an important pathological feature of diabetic
retinopathy (7,8). At early stages of diabetic retinopathy,
increased production of extracellular matrix has been
shown to contribute to the capillary basement membrane
thickening (42). At advanced stages of diabetic retinopa-
thy, ﬁbrosis can result in contraction and retinal detach-
ment, a major cause of blindness in diabetic retinopathy
(7,8). The molecular mechanism for retinal ﬁbrosis in
diabetic retinopathy is not clear. CTGF is a major ﬁbro-
genic factor, and its overexpression has been found to play
a key role in the basement membrane thickening in
diabetic retinopathy models (14,16). CTGF upregulates
production of extracellular matrix proteins such as ﬁ-
bronectin (43,44). Therefore, CTGF is considered a prom-
ising target for treating retinal ﬁbrosis in diabetic
retinopathy. The present study identiﬁed SERPINA3K as
an endogenous inhibitor of CTGF and, thus, an antiﬁbro-
genic factor in the retina. On the other hand, CTGF has
been reported to bind to Wnt receptor/coreceptor (45).
However, the function of CTGF in canonical Wnt signaling
is still controversial (33,45). Despite the possible feedback
regulation by CTGF, blockade of Wnt signaling by
SERPINA3K should result in a decrease of CTGF levels
and inhibition of ﬁbrogenesis, which supports our conclu-
sion (i.e., the antiﬁbrogenic effect of SERPINA3K is medi-
ated, at least in part, through the Wnt pathway).
Our previous studies have shown that retinal levels of
SERPINA3K are decreased in STZ-induced diabetic rats
after 1, 2, and 4 months of diabetes (6). In the same animal
model, CTGF overexpression was found in the diabetic rat
retinas 3 months after STZ injection (13), correlating with
the decrease of SERPINA3K. The disturbed balance be-
tween proﬁbrogenic factor CTGF and anti-ﬁbrogenic factor
SERPINA3K may represent a new pathogenic mechanism for
the basement membrane thickening in diabetic retinopathy.
Wnt signaling is involved in ocular diseases, such as
vasculature disorders in the retina (23). Our recent study
showed that activation of the Wnt pathway also plays a
pathogenic role in subretinal neovascularization in an
animal model of wet age-related macular degeneration
(AMD) (46). The role of Wnt signaling in pathological
ﬁbrosis has been revealed in some tissues (e.g., the lung)
(24). However, in most ocular diseases such as diabetic
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FIG. 6. SERPINA3K blocked the Wnt ligand-induced CTGF overexpres-
sion. A and B: HTERT RPE-1 cells were exposed to 50% control L-cell
medium (LM) or 50% Wnt3a conditioned medium (WM) for1h( A)o r
2h( B), with 100 nmol/l SERPINA3K or BSA. The same amounts of total
cellular proteins (100 g) (A) or cytosolic proteins (20 g) (B) were
blotted separately with antibodies speciﬁc for p-LRP6 and total LRP6
(A), or for -catenin (B). C: The cells were transfected with the
TOPFLASH vector, followed by exposure to the LM or WM containing
1,000 nmol/l BSA or SERPINA3K for 24 h. The TOPFLASH activity was
measured using luciferase assay (means  SD, n  3, *P < 0.05). D:
HTERT RPE-1 cells were exposed to LM and WM media with 100 nmol/l
SERPINA3K or BSA. After culture for 24 h, CTGF levels were mea-
sured by Western blot analysis.
A NOVEL ANTIFIBROGENIC FACTOR
1814 DIABETES, VOL. 59, JULY 2010 diabetes.diabetesjournals.orgretinopathy, the role of Wnt signaling, especially the
association between Wnt signaling and retinal ﬁbrosis
remains obscure. Here, our results showed that cytosolic
-catenin, an essential effector of the canonical Wnt path-
way, is accumulated in both diabetic retinas and in the
high-glucose–treated retinal cells. Phosphorylation of
LRP6 is an early, yet essential, step in activation of the
canonical Wnt pathway, as the phosphorylation sites in the
LRP6 intracellular domain are known to create inducible
docking sites for Axin, leading to stabilization of -catenin
in the cytosol and transduction of the extracellular Wnt
signal into intracellular compartments (40,47). Our results
showed that phosphorylated LRP6 levels were increased
under high-glucose conditions. In the hyperglycemia mod-
els, the induction of Wnt signaling activity was accompa-
nied by CTGF overexpression. Same as the high-glucose
exposure, Wnt3a ligand also induced Wnt signaling activa-
tion and upregulated CTGF expression, while DKK1, a
speciﬁc inhibitor of the Wnt pathway, blocked the Wnt
pathway activation. Therefore, our results revealed that
Wnt signaling is activated in diabetic retinopathy, which
may be responsible for CTGF overexpression and retinal
ﬁbrosis.
Since DKK-1 is a commonly accepted, speciﬁc inhibitor
of the canonical Wnt pathway, DKK-1 was used to specif-
ically attenuate the Wnt signaling activation and further to
reveal the role of Wnt signaling in high-glucose–induced
CTGF overexpression. DKK-1 has been reported to induce
the internalization of LRP6 (48). To investigate the mech-
anism for the SERPINA3K effect on the Wnt pathway, we
have measured several components of the Wnt pathway at
different levels of the cascade. Further, we measured the
cell surface level of LRP6 to determine the internalization
of LRP6 using extracellular biotin labeling. Similar to
DKK-1, preincubation of the cells with SERPINA3K de-
creased the cell surface level of LRP6 (online appendix
Fig. S5C). This result suggests that induction of LRP6
internalization may represent a mechanism responsible, at
least partially, for the inhibition of LRP6 phosphorylation
by SERPINA3K.
There are 19 Wnt ligands, many of which function as
agonists of the Fz/LRP5/6 receptor complex and, thus,
activate Wnt/-catenin signaling (49). On the other hand,
some natural inhibitors of the Wnt pathway such as DKK
family members and IGFbinding protein-4 have been iden-
tiﬁed (50–52). Here, we showed that SERPINA3K blocks
the Wnt pathway activation induced by high glucose and
by Wnt ligands, suggesting that SERPINA3K is a novel
endogenous inhibitor of the Wnt pathway. SERPINA3K is
known to speciﬁcally bind to tissue kallikrein, forming a
covalent complex and inhibiting proteolytic activities of
tissue kallikrein (3). Through interactions with the kal-
likrein-kinin system, SERPINA3K participates in the regu-
lation of blood pressure and local blood ﬂow (4). However,
the kallikrein-binding activity cannot explain the broad
functions of SERPINA3K, such as antiangiogenic and
anti-inﬂammatory activities (5,41). In addition, some of
these functions have proven to be independent of interac-
tions with tissue kallikrein (5). The present study demon-
strates that SERPINA3K has a potent Wnt antagonist
activity. Since the Wnt pathway regulates multiple patho-
logical processes, including angiogenesis, inﬂammation,
and ﬁbrosis, the Wnt antagonizing activity of SERPINA3K
may represent a unifying mechanism responsible for the
broad beneﬁcial effects of this serpin. As an endogenous
inhibitor of the Wnt pathway, this serpin molecule may
have therapeutic potential.
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